Abstract:Psychotic depression (PD) is a severe mental disorder leading to functional disability and high risk of suicide, but very little is known about the comparative effectiveness of medications used in its maintenance treatment. The objective of this study was to investigate the comparative effectiveness of specific antipsychotics and antidepressants, and their combinations, on the risk of psychiatric hospitalization among persons with PD in routine care. Persons aged 16‐65 years with a first‐time diagnosis of PD were identified from Finnish (years 2000‐2018) and Swedish (years 2006‐2021) nationwide registers of inpatient care, specialized outpatient care, sickness absence, and disability pension. The main exposures were specific antipsychotics and antidepressants, and the main outcome measure was psychiatric hospitalization as a marker of severe relapse. The risk of hospitalization associated with periods of use vs. non‐use of medications (expressed as adjusted hazard ratio, aHR) was assessed by a within‐individual design, using each individual as his/her own control, and analyzed with stratified Cox models. The two national cohorts were first analyzed separately, and then combined using a fixed‐effect meta‐analysis. The Finnish cohort included 19,330 persons (mean age: 39.8±14.7 years; 57.9% women) and the Swedish cohort 13,684 persons (mean age: 41.3±14.0 years; 53.5% women). Individual antidepressants associated with a decreased risk of relapse vs. non‐use of antidepressants were bupropion (aHR=0.73, 95% CI: 0.63‐0.85), vortioxetine (aHR=0.78, 95% CI: 0.63‐0.96) and venlafaxine (aHR=0.92, 95% CI: 0.86‐0.98). Any long‐acting injectable antipsychotic (LAI) (aHR=0.60, 95% CI: 0.45‐0.80) and clozapine (aHR=0.72, 95% CI: 0.57‐0.91) were associated with a decreased risk of relapse vs. non‐use of antipsychotics. Among monotherapies, only vortioxetine (aHR=0.67, 95% CI: 0.47‐0.95) and bupropion (aHR=0.71, 95% CI: 0.56‐0.89) were associated with a significantly decreased risk of relapse vs. non‐use of both antidepressants and antipsychotics. In an exploratory analysis of antidepressant‐antipsychotic combinations, a decreased relapse risk was found for amitriptyline‐olanzapine (aHR=0.45, 95% CI: 0.28‐0.71), sertraline‐quetiapine (aHR=0.79, 95% CI: 0.67‐0.93) and venlafaxine‐quetiapine (aHR=0.82, 95% CI: 0.73‐0.91) vs. non‐use of antidepressants and antipsychotics. Benzodiazepines and related drugs (aHR=1.29, 95% CI: 1.24‐1.34) and mirtazapine (aHR=1.17, 95% CI: 1.07‐1.29) were associated with an increased risk of relapse. These data indicate that, in the maintenance treatment of PD, bupropion, vortioxetine, venlafaxine, any LAI, clozapine, and only few specific antidepressant‐antipsychotic combinations are associated with a decreased risk of relapse. These findings challenge the current recommendation by treatment guidelines to combine an antipsychotic with an antidepressant (without further specification) as standard treatment in PD.

Exploring real-world prescribing patterns for maintenance treatment in bipolar disorders: a focus on antidepressants and benzodiazepines

Prescribing Patterns Of Antidepressants, Antipsychotics And Mood Stabilizers In Bipolar Patients Misdiagnosed With Major Depressive Disorder In China

Treatment of bipolar depression: clinical practice vs. adherence to guidelines-data from a Bavarian drug surveillance project

Evidence-based Pharmacological Treatment in the Maintenance Phase of the Type I Bipolar Disorder: Anticonvulsants or Antipsychotics?

Medication nonadherence in bipolar disorder: a narrative review

The identification of biomarkers predicting acute and maintenance lithium treatment response in bipolar disorder: A plea for further research attention

Prior psychiatric morbidity and differential psychopharmacological treatment patterns: Exploring the heterogeneity of bipolar disorder in a nationwide study of 9594 patients

Exploring Patterns of Medication Usage in Affective Disorder Patients: A Comprehensive Investigation at a Psychiatry Outpatient Clinic of a Tertiary Care Hospital

Medication Adherence in Patients with Bipolar Disorder: A Comprehensive Review

Guidelines Concordance of Maintenance Treatment in Euthymic Patients with Bipolar Disorder: Data from the National Bipolar Mania Pathway Survey (BIPAS) in Mainland China

Real‐world effectiveness of antidepressants, antipsychotics and their combinations in the maintenance treatment of psychotic depression. Evidence from within‐subject analyses of two nationwide cohorts

Clinical use of mood stabilizers beyond treatment for bipolar disorder: The REAP-MS study

Bipolar disorder prevalence and psychotropic medication utilisation in Hong Kong and the United Kingdom

A Cross-sectional Analysis of Patterns and Predictors of Medication Adherence in Bipolar Disorder: Single Center Experience from South India

Duration of Adjunctive Antidepressant Maintenance in Bipolar I Depression

Comparative efficacy of pharmacological treatments in the maintenance treatment of bipolar disorder: a systematic review and network Meta-analysis

Real-world Effectiveness of Pharmacologic Treatments for the Prevention of Rehospitalization in a Finnish Nationwide Cohort of Patients With Bipolar Disorder

Therapeutic approaches employing natural compounds and derivatives for treating bipolar disorder: emphasis on experimental models of the manic phase

Prescribing patterns in patients with obsessive-compulsive disorder: Retrospective, single-center study

PMH80 UTILIZATION PATTERN AND TREATMENT ADHERENCE WITH MOOD STABILIZERS AND ATYPICAL ANTIPSYCHOTICS AMONG PEDIATRIC PATIENTS WITH BIPOLAR DISORDER: A RETROSPECTIVE CLAIMS-BASED STUDY

Bipolar Disorder and Outcomes of Monotherapy with Lithium, Valproate, Quetiapine, Olanzapine, Venlafaxine, and Citalopram